Peptide T data

PTD (Dee Why, N.S.W., Australia) announced results of Peptide T in 146 patients in a German trial, with a statistically significant improvement over placebo in patients who were initially impaired on certain neuropsychological tests.

The drug resulted in improved scores in one of the three tests, the company said, while self-evaluated ratings of peripheral neuropathy also improved with a statistically significant change. ...